Biotech

All Articles

Analysts dig into Avidity's DMD win, showing nuances in information

.Avidity Biosciences pleased capitalists with period 1/2 records in Duchenne muscle dystrophy (DMD) ...

Actinogen's cortisol blocker falls short phase 2 anxiety research study

.Actinogen Medical's cortisol blocker has actually missed the primary endpoint of a stage 2 study in...

Bivictrix decides going personal only way to take ADC in to clinic

.Antibody-drug conjugates (ADCs) have been at the facility of lots of a billion-dollar biobuck licen...

TPG leadings up funds to $580M for investments around lifestyle sciences

.Resource supervisor TPG, which has actually assisted biotechs such as Sionna Rehabs and Santa Ana B...

Merck ceases phase 3 TIGIT test in lung cancer for futility

.Merck &amp Co.'s TIGIT course has actually suffered an additional problem. Months after shuttering ...

After a challenging year, Exscientia folds in to Recursion

.After a year determined by pipeline cuts, the departure of its CEO and also discharges, Exscientia ...

Cullinan, after $25M bargain, hands back bispecific to Harbour

.Cullinan Therapeutics was actually impressed good enough along with Port BioMed's bispecific immune...

A better check out Fierce Biotech's Intense 15

.In this particular week's episode of "The Best Pipe," we're diving in to Strong Biotech's annual To...

Lilly encounters phase 2 failing of tau-targeting med

.The confetti is still flying coming from Eli Lilly's event celebrating the approval of Alzheimer's ...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Invite to recently's Chutes &amp Ladders, our summary of considerable leadership hirings, shootings...